Difficult to answer of course. However, there's still execution risk in ROW and NNZ. Interestingly, the valuation model suggests NA rights are worth circa $2bn. So, market seems to only reflect what's 'in the bag' ie NA rights.
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-4550
-
- There are more pages in this discussion • 6,317 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.88 |
Change
0.430(2.10%) |
Mkt cap ! $2.613B |
Open | High | Low | Value | Volume |
$20.56 | $20.89 | $20.54 | $808.2K | 39.07K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 28 | $20.87 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.88 | 409 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 67 | 20.870 |
5 | 173 | 20.860 |
3 | 121 | 20.850 |
3 | 224 | 20.840 |
3 | 247 | 20.830 |
Price($) | Vol. | No. |
---|---|---|
20.900 | 1524 | 8 |
20.910 | 327 | 5 |
20.920 | 224 | 3 |
20.930 | 120 | 2 |
20.940 | 326 | 4 |
Last trade - 10.26am 16/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online